Cogent Biosciences: 3 NDAs Create A Time-To-Market Moat (NASDAQ:COGT)
· seekingalpha.com
Cogent Biosciences is positioned to commercialize bezuclastinib across three indications, leveraging a single precision molecule for multi-market entry. Learn more about COGT stock here.
I am bullish on Cogent Biosciences, Inc. ( COGT ) as it transitions from a single-asset, clinical-stage biotech to a potential multi-indication commercial organ...